Physician profile
Patrick M Kwon
NPI 1558669812
$98,467.19
in general payments reported to CMS, 2019-2025
23 companies · $77K in 2025
The $77K reported for 2025 was more than what 96% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.58 · 2020: $102 · 2021: $1,136 · 2022: $513 · 2023: $532 · 2024: $19K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Travel and Lodging: $9,444 · Food and Beverage: $6,126 · Consulting Fee: $3,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,625.00 |
| Travel and Lodging | $9,444.03 |
| Food and Beverage | $6,125.57 |
| Consulting Fee | $3,437.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $80,022.84 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $14,135.87 | 2025 | Uplizna |
| Abbvie INC. | $1,373.34 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $840.00 | 2021 | |
| Grifols Shared Services North America, INC. | $562.63 | 2022-2025 | Gamunex-C |
| Merz Pharmaceuticals, LLC | $324.70 | 2021-2025 | Xeomin |
| Allergan, INC. | $220.08 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $148.99 | 2025 | |
| Genzyme Corporation | $138.46 | 2025 | |
| Grifols USA, LLC | $109.13 | 2022-2025 | Gamunex-C |
| Ucb, INC. | $99.64 | 2025 | Zilbrysq, Rystiggo |
| Tanabe Pharma America, INC. | $70.36 | 2023-2025 | Radicava |
| Pfizer INC. | $59.96 | 2021-2023 | |
| Biogen, INC. | $58.65 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.00 | 2024-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $46.11 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $45.70 | 2023-2025 | Zonisade, Eprontia |
| Csl Behring | $43.26 | 2019-2021 | |
| Janssen Biotech, INC. | $27.23 | 2025 | |
| Viiv Healthcare Company | $25.33 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.54 | 2023 | Keveyis |
| Alnylam Pharmaceuticals INC. | $20.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $18.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.